Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP)

$5.68 -0.07 (-1.26%)
Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
Kconn52
Kconn52 Aug. 7 at 2:09 PM
$FBIOP net of the currently accumulated and unpaid dividend, this is now selling for about $4.36 share. With the common selling for $1.87 this is at 2.3x and this has a liquidation preference of $25 (all ahead of any value to the common). The $DERM value alone virtually guarantees this gets paid out. IMO that is a market anomaly of incredible proportions. Long, long , long $FBIOP
1 · Reply
Zellchair
Zellchair Aug. 6 at 10:48 AM
$FBIO $FBIOP There is absolutely nothing to see here... https://finance.yahoo.com/news/menkes-disease-market-analysis-forecast-131400555.html https://www.researchandmarkets.com/reports/6096996/menkes-disease-market-global-regional
1 · Reply
Zellchair
Zellchair Aug. 6 at 10:19 AM
$FBIO $FBIOP "Novo Nordisk's Knudsen: Balance sheet strong for acquisitions - We have one of the lowest debt ratios in pharma... So just by using our balance sheet, we have very significant firepower, Knudsen says." If only there was something they could buy to broaden their pipeline... https://www.bloomberg.com/search?query=novo%20nordisk
0 · Reply
Sawnchey
Sawnchey Aug. 6 at 9:20 AM
$DERM $FBIO $FBIOP I am going to mention amother stock here, it's not to plug, but to give context to my thoughts on DERM. The most successful launch story I have been following this past year is MDGL. They have different circumstances, but their approach and focus closely mirrors what I hear and like from Journey. MDGL were first to market with their product, it's a blockbuster indication for MASH. Their US sales went as follows: Q2 2024 - 15m Q3 2024 - 62m Q4 2024 - 103m Q1 2025 - 137m Q2 2025 - 213m The scale of revenue is different, but they (like Journey) took a diligent approach to product education, market access and broad publication of data. With Journey, I am seeing a similar pace of payor coverage, dissemination of their excellent clinical data, and from day 1 they had an experienced sales force with existing relationships with prescribers. Q2 figures may not be enormous, but I am expecting steady growth quarter-on-quarter. Plus they only need about 4m to reach profit.
0 · Reply
Zellchair
Zellchair Aug. 6 at 8:53 AM
$FBIO $FBIOP SOT? WITHDRAWN https://clinicaltrials.gov/study/NCT06133010 Of all the indications Triplex is currently being studied, only the smallest indication, HCT, remains for mRNA-1647 (congenital CMV infection different story but Triplex is not in any studies there). And there, in HCT, Moderna is years behind Triplex, even if they were to present positive P2 data... https://clinicaltrials.gov/study/NCT05683457
1 · Reply
Zellchair
Zellchair Aug. 6 at 8:40 AM
$FBIO $FBIOP HHS & FDA is watching you mRNA-1647! The entire Helocyte/Triplex wave is heading towards a potential incredible dream scenario within HCMV. A 50-60 year marathon where all competitors drop out while your energy and strength just continue to be confirmed along the way with a little bit left to the finish line... https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html https://x.com/SecKennedy/status/1952851097019633766
0 · Reply
Zellchair
Zellchair Aug. 6 at 6:06 AM
$FBIO $FBIOP "What Are Common Oral Medications For Rosacea?" Not unexpectedly, the answer in the future seems to be EMROSI from $DERM https://www.youtube.com/watch?v=-5r1bcxEOKY
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:45 PM
$FBIO $FBIOP Journey Medical's $DERM CEO Claude Maraoui will participate in the Emerging Growth Conference August 20/21 (online). Don't miss it. https://x.com/EmergingGrowthC/status/1952767587604898125 https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=derm
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:32 PM
$FBIO $FBIOP Speaking of Dotinurad, there's absolutely nothing to see here... Only KRYSTEXXA which just landed in Q2 sales for $349M (yes, in the quarter...)... Are there any of you left who think Fortress won't be able to pay out $2.08M in dividends per quarter in FBIOP in the future? https://investors.amgen.com/news-releases/news-release-details/amgen-reports-second-quarter-2025-financial-results
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:20 PM
$FBIO $FBIOP I'll let this link speak for itself... https://tradingeconomics.com/nvo:us:cash-and-equivalent
0 · Reply
Latest News on FBIOP
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 2 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 3 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 3 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIO

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 4 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 17, 2025, 8:55 AM EDT - 5 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIO

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 27, 2025, 8:30 AM EST - 6 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIO

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 7 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIO

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 14, 2024, 4:10 PM EST - 9 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech to Participate in October 2024 Investor Conferences

Sep 26, 2024, 8:30 AM EDT - 11 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Sep 20, 2024, 8:30 AM EDT - 11 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

FBIO

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

FBIO

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Jul 5, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIO

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 10:42 PM EST - 2 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

Aug 9, 2022, 9:05 PM EDT - 3 years ago

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

FBIO

Plenty Of Further Upside In Fortress Biotech

Mar 19, 2019, 12:01 PM EDT - 6 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO

Kconn52
Kconn52 Aug. 7 at 2:09 PM
$FBIOP net of the currently accumulated and unpaid dividend, this is now selling for about $4.36 share. With the common selling for $1.87 this is at 2.3x and this has a liquidation preference of $25 (all ahead of any value to the common). The $DERM value alone virtually guarantees this gets paid out. IMO that is a market anomaly of incredible proportions. Long, long , long $FBIOP
1 · Reply
Zellchair
Zellchair Aug. 6 at 10:48 AM
$FBIO $FBIOP There is absolutely nothing to see here... https://finance.yahoo.com/news/menkes-disease-market-analysis-forecast-131400555.html https://www.researchandmarkets.com/reports/6096996/menkes-disease-market-global-regional
1 · Reply
Zellchair
Zellchair Aug. 6 at 10:19 AM
$FBIO $FBIOP "Novo Nordisk's Knudsen: Balance sheet strong for acquisitions - We have one of the lowest debt ratios in pharma... So just by using our balance sheet, we have very significant firepower, Knudsen says." If only there was something they could buy to broaden their pipeline... https://www.bloomberg.com/search?query=novo%20nordisk
0 · Reply
Sawnchey
Sawnchey Aug. 6 at 9:20 AM
$DERM $FBIO $FBIOP I am going to mention amother stock here, it's not to plug, but to give context to my thoughts on DERM. The most successful launch story I have been following this past year is MDGL. They have different circumstances, but their approach and focus closely mirrors what I hear and like from Journey. MDGL were first to market with their product, it's a blockbuster indication for MASH. Their US sales went as follows: Q2 2024 - 15m Q3 2024 - 62m Q4 2024 - 103m Q1 2025 - 137m Q2 2025 - 213m The scale of revenue is different, but they (like Journey) took a diligent approach to product education, market access and broad publication of data. With Journey, I am seeing a similar pace of payor coverage, dissemination of their excellent clinical data, and from day 1 they had an experienced sales force with existing relationships with prescribers. Q2 figures may not be enormous, but I am expecting steady growth quarter-on-quarter. Plus they only need about 4m to reach profit.
0 · Reply
Zellchair
Zellchair Aug. 6 at 8:53 AM
$FBIO $FBIOP SOT? WITHDRAWN https://clinicaltrials.gov/study/NCT06133010 Of all the indications Triplex is currently being studied, only the smallest indication, HCT, remains for mRNA-1647 (congenital CMV infection different story but Triplex is not in any studies there). And there, in HCT, Moderna is years behind Triplex, even if they were to present positive P2 data... https://clinicaltrials.gov/study/NCT05683457
1 · Reply
Zellchair
Zellchair Aug. 6 at 8:40 AM
$FBIO $FBIOP HHS & FDA is watching you mRNA-1647! The entire Helocyte/Triplex wave is heading towards a potential incredible dream scenario within HCMV. A 50-60 year marathon where all competitors drop out while your energy and strength just continue to be confirmed along the way with a little bit left to the finish line... https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html https://x.com/SecKennedy/status/1952851097019633766
0 · Reply
Zellchair
Zellchair Aug. 6 at 6:06 AM
$FBIO $FBIOP "What Are Common Oral Medications For Rosacea?" Not unexpectedly, the answer in the future seems to be EMROSI from $DERM https://www.youtube.com/watch?v=-5r1bcxEOKY
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:45 PM
$FBIO $FBIOP Journey Medical's $DERM CEO Claude Maraoui will participate in the Emerging Growth Conference August 20/21 (online). Don't miss it. https://x.com/EmergingGrowthC/status/1952767587604898125 https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=derm
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:32 PM
$FBIO $FBIOP Speaking of Dotinurad, there's absolutely nothing to see here... Only KRYSTEXXA which just landed in Q2 sales for $349M (yes, in the quarter...)... Are there any of you left who think Fortress won't be able to pay out $2.08M in dividends per quarter in FBIOP in the future? https://investors.amgen.com/news-releases/news-release-details/amgen-reports-second-quarter-2025-financial-results
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:20 PM
$FBIO $FBIOP I'll let this link speak for itself... https://tradingeconomics.com/nvo:us:cash-and-equivalent
0 · Reply
Zellchair
Zellchair Aug. 5 at 8:00 PM
$FBIO $FBIOP And to you who keep emailing about that BT Slingsby having nothing to do with Crystalys today or historically... I'm not stupid. The truth exists.
0 · Reply
Zellchair
Zellchair Aug. 5 at 7:46 PM
$FBIO $FBIOP Do you believe me now about the Serie A round in Part 8? You can't get two P3s confirmed without financial guarantees to finance them with...
1 · Reply
Zellchair
Zellchair Aug. 5 at 7:09 PM
$FBIO $FBIOP Once again, breaking news that is of stratospheric importance for Fortress: Part 9 - Fortress Biotech $FBIOP - Transforming news as Dotinurad's next step is confirmed with two separate P3s in US https://zellchair.substack.com/p/fortress-biotech-fbiop-transforming
0 · Reply
Zellchair
Zellchair Aug. 5 at 6:09 PM
$FBIO $FBIOP August - 14 × $0.1953 = $2.7342 Dividend per share New month and an accumulated dividend in $FBIOP which at the current share price of $7.18 gives 38.08% in dividend but who's counting... Q report next week. I don't think they will announce that the dividend will resume then (for September), but, there are several reasons that it is not completely ruled out.
0 · Reply
Zellchair
Zellchair Aug. 5 at 4:03 PM
$FBIO $FBIOP $CKPT Read the last paragraph here if you want a little more detail about why Checkpoint first received its CRL from the FDA. https://www.fiercepharma.com/pharma/weak-evidence-and-unpleasant-odors-fda-sheds-light-drug-refusal-process
0 · Reply
Zellchair
Zellchair Aug. 5 at 1:01 PM
$FBIO $FBIOP $DERM What are you even talking about? Do you let AI control your responses? What does FY2024 already reported results mean for my post about the CEO's response about EMROSIS's expected sales floor 2025-03-24-2026-03-24 (TTM)?
1 · Reply
Zellchair
Zellchair Aug. 5 at 12:51 PM
$FBIO $FBIOP $DERM These last three posts were from my first Substack on May 5th (link) where I gave Journey Medical a lot of light. When the share price remains at a low $7 and EMROSI already sold for $2.07M in Q1, and therefore only needs to sell for $2.93M in Q2 to be in phase (for EMROSI) for ROTH MKM previous PT $11 which expires (has reached 1 year) next Wednesday 13/8, the numbers and the text are equally relevant. https://zellchair.substack.com/p/fortress-biotech-preferred-fbiop
0 · Reply
Zellchair
Zellchair Aug. 5 at 12:47 PM
$FBIO $FBIOP $DERM ROTH MKH latest Estimated EPS for Journey Medical (April 3, 2025), where it lowered its forecasts for ACCUTANE and QBREXZA given the increased competition mentioned above: 2026: $2.18 EPS 2027: $3.32 EPS 2028: $5.18 EPS P/E based on $7.03 in DERM (2025-05-05) share price: 2026: P/E 3.22 2027: P/E 2.11 2028: P/E 1.35
0 · Reply
Zellchair
Zellchair Aug. 5 at 12:46 PM
$FBIO $FBIOP $DERM When ROTH MKM analysed Journey in August 2024, they assumed that the price for EMROSI would be in line with ORACEA's price, and progressed the following sales development for EMROSI in the coming years: 2025 Q1: $0M Q2: $5M Q3: $14M Q4: $21M Total: $40M 2026 Total: $80M 2027 Total: ? 2028 Total: $200M If they received $19M cash upfront in a sales deal (up to $45M in total) in parts of Asia for QBREXZA, what can EMROSI bring in (excluding BRIC and CIS)? A deal that includes, for example, the entire EU and UK? When it comes to sales deals for both EMROSI and other assets in the portfolio, Journey has been willing to point out in every conference call or investor presentation that they are in active discussions with several partners for various possible deals.
0 · Reply
Zellchair
Zellchair Aug. 5 at 12:43 PM
$FBIO $FBIOP $DERM In response to a direct question from me at an Investor Conference last year, CEO Maraouis answered “Yes” to the question of whether EMROSI will do $50M in sales in the first year (trailing twelve months).
1 · Reply
Zellchair
Zellchair Aug. 4 at 10:01 PM
$FBIO $FBIOP $CKPT "Unloxcyt would have some prescriber overlap with Odomzo" https://www.icicidirect.com/mailcontent/idirect_sunpharma_q1fy26.pdf
0 · Reply
Zellchair
Zellchair Aug. 4 at 8:48 PM
$FBIO $FBIOP "historically" is a meaningless choice of words by you if you don't put it in any context. Since the dividend was paused, a deal with Dotinurad has been made and all of its development costs have disappeared. EMROSI and UNLOXCYT were months away from even receiving a possible FDA approval and Checkpoint was almost a year away from being sold (with its development costs etc). The CUTX-101 NDA application had not even been submitted to the FDA. This is just to name a few of the bigger things. When Fortress reinstate the dividend in FBIOP, it will be traded according to the assessment of future opportunities to continue paying its dividend. Those opportunities are already considerably greater today than they were according to your "historically" time you refer to.
1 · Reply